Latest News about TAK
Recent news which mentions TAK
What's Going On With Takeda Stock On Friday?
August 22, 2025
From Benzinga
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
August 21, 2025
From Benzinga
From Benzinga
Earnings Scheduled For July 30, 2025
July 30, 2025
From Benzinga
From Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
From Benzinga
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
April 02, 2025
From Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
March 27, 2025
From Benzinga
From Benzinga
From Benzinga
Earnings Scheduled For January 30, 2025
January 30, 2025
From Benzinga
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
January 28, 2025
From Benzinga
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
January 15, 2025
From Benzinga
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
December 27, 2024
From Benzinga
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
December 18, 2024
From Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
December 03, 2024
From Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
November 14, 2024
From Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
November 12, 2024
From Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
October 17, 2024
From Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
October 04, 2024
From Benzinga
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
From Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
From Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
From Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
From Benzinga
From Benzinga
Tickers
TAK
From InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.